Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Journal: Investigational new drugs
Published: December 19, 2016
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 10, 2016
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Journal: Targeted oncology
Published: May 08, 2016
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 15, 2014
Showing 1-4 of 4
Last Updated: 09/26/2026